How to Actually Run a Cannabis Clinical Trial in Palliative Care
Designing cannabis trials for dying patients involves six unique challenges beyond standard clinical research—from navigating cannabis legislation to managing product variability and compassionate access.
Quick Facts
What This Study Found
This paper is a practical roadmap for researchers, drawn from the investigators' experience running a Phase I/IIb trial of vaporized cannabis for cancer anorexia. Using action research methodology, they documented the challenges they encountered and synthesized them into six key design considerations.
The six considerations: (1) Operating within medicinal cannabis legislation—which varies by jurisdiction and is often changing mid-trial. (2) Bioethical considerations unique to cannabis (stigma, patient expectations, the politics of evidence). (3) Feasibility challenges in palliative populations (recruitment, retention, cognitive capacity to consent). (4) Pharmacological complexity (variable plant composition, limited standardization, drug interactions). (5) Product requirements (quality control, dosing consistency, shelf life). (6) Regulatory hurdles specific to cannabis as an investigational product.
Palliative care adds layers of complexity that don't exist in other cannabis research: patients are seriously ill, may deteriorate rapidly during a trial, have complex medication regimens, and face existential concerns that shape their relationship with any potential treatment. The intersection of cannabis complexity and palliative care complexity creates unique challenges that this paper aims to help future researchers navigate.
Key Numbers
6 key design considerations identified. Phase I/IIb trial of vaporized cannabis for cancer anorexia. Action research audit trail from investigator meetings.
How They Did This
Action research methodology applied to a Phase I/IIb trial of vaporized medicinal cannabis for anorexia in advanced cancer (ACTRN12616000516482). Notes from trial investigator meetings served as an audit trail. Data integrated and synthesized to identify key design considerations.
Why This Research Matters
The evidence base for cannabis in palliative care can only grow if researchers can actually conduct the trials. Many well-intentioned cannabis studies fail due to regulatory, logistical, or ethical barriers that could have been anticipated. This paper provides a practical blueprint for navigating those barriers, potentially accelerating the pace of palliative cannabis research.
The Bigger Picture
This is the third paper from the same trial team: RTHC-00194 covered patient involvement in design, RTHC-00177 captured patient experiences with the product. Together, they form a comprehensive case study of how to conduct cannabis research in palliative care—from design philosophy (consumer contribution) through practical challenges (this paper) through patient experience (qualitative findings). For a field where many trials never get off the ground, this kind of methodological transparency is valuable.
What This Study Doesn't Tell Us
Based on a single trial in one country (Australia), where cannabis regulations and palliative care systems may differ from other jurisdictions. Action research methodology provides rich practical insights but isn't empirically generalizable. The considerations are drawn from experience with vaporized flower—trials using oils, edibles, or synthetic cannabinoids would face different challenges.
Questions This Raises
- ?Could standardized regulatory pathways for cannabis research reduce the burden described here?
- ?Would synthetic cannabinoids avoid some product variability issues while maintaining efficacy?
- ?How do different countries' cannabis regulations compare in terms of research feasibility?
Trust & Context
- Key Stat:
- Evidence Grade:
- Action research methodology providing a practical framework—valuable for research design but not a source of clinical efficacy data.
- Study Age:
- Published in 2025 in the Journal of Pain and Symptom Management, reflecting current regulatory and practical challenges.
- Original Title:
- Design Considerations for Medicinal Cannabis Clinical Trials in People Receiving Palliative Care.
- Published In:
- Journal of pain and symptom management, 69(5), e395-e408 (2025) — The Journal of Pain and Symptom Management is a reputable journal focusing on pain management and symptom control in clinical practice.
- Authors:
- Razmovski-Naumovski, Valentina(3), Martin, Jennifer H(4), Chye, Richard(2), Phillips, Jane L, Lintzeris, Nicholas, Solowij, Nadia, Lee, Jessica, Lovell, Melanie, Noble, Bev, Galettis, Peter, Brown, Linda, Fazekas, Belinda, Clark, Katherine, Luckett, Tim, McCaffrey, Nikki, Currow, David C, Agar, Meera R
- Database ID:
- RTHC-07451
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07451APA
Razmovski-Naumovski, Valentina; Martin, Jennifer H; Chye, Richard; Phillips, Jane L; Lintzeris, Nicholas; Solowij, Nadia; Lee, Jessica; Lovell, Melanie; Noble, Bev; Galettis, Peter; Brown, Linda; Fazekas, Belinda; Clark, Katherine; Luckett, Tim; McCaffrey, Nikki; Currow, David C; Agar, Meera R. (2025). Design Considerations for Medicinal Cannabis Clinical Trials in People Receiving Palliative Care.. Journal of pain and symptom management, 69(5), e395-e408. https://doi.org/10.1016/j.jpainsymman.2025.02.009
MLA
Razmovski-Naumovski, Valentina, et al. "Design Considerations for Medicinal Cannabis Clinical Trials in People Receiving Palliative Care.." Journal of pain and symptom management, 2025. https://doi.org/10.1016/j.jpainsymman.2025.02.009
RethinkTHC
RethinkTHC Research Database. "Design Considerations for Medicinal Cannabis Clinical Trials..." RTHC-07451. Retrieved from https://rethinkthc.com/research/razmovski-naumovski-2025-design-considerations-for-medicinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.